Clinical Trials in Candiolo, Italy
1 recruiting
Showing 1–20 of 31 trials
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled63 locationsNCT06618287
Recruiting
Not Applicable
Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC
Fondazione del Piemonte per l'Oncologia160 enrolled6 locationsNCT07479277
Recruiting
Not Applicable
Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma.
Lung AdenocarcinomaLepidic-Predominant Lung Adenocarcinoma
Fondazione del Piemonte per l'Oncologia30 enrolled1 locationNCT07479095
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Janssen Research & Development, LLC380 enrolled45 locationsNCT07230691
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
Breast CancerOvarian CancerColo-rectal Cancer+2 more
Fondazione del Piemonte per l'Oncologia850 enrolled1 locationNCT07469709
Recruiting
Phase 2Phase 3
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie430 enrolled53 locationsNCT07155187
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Not Applicable
A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity
Rectal AdenocarcinomaNon Metastatic
Fondazione del Piemonte per l'Oncologia200 enrolled1 locationNCT06952101
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb596 enrolled185 locationsNCT07100080
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled288 locationsNCT06868277
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Cervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMicrosatellite Stable Colorectal Cancer
Bristol-Myers Squibb949 enrolled50 locationsNCT04895709
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Gilead Sciences695 enrolled204 locationsNCT06801834
Recruiting
Phase 2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Metastatic CancerAdvanced CancerMalignant Neoplasm of Lung
Mirati Therapeutics Inc.200 enrolled120 locationsNCT05853575
Recruiting
Phase 2
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo520 enrolled119 locationsNCT06330064
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled214 locationsNCT07128199
Recruiting
Phase 1
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.470 enrolled39 locationsNCT05983432
Recruiting
Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626